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Abstract: The aim of this study was to investigate the effect of fenfluramine (FEN) administered at single and repeated doses on
brain, stomach and plasma serotonin (5-Hydroxytryptamine, 5-HT) levels in rats. FEN was injected intraperitoneally at single doses
(1, 3 and 10 µmol kg-1) and given orally at repeated doses (1.25, 5 and 10 mg kg-1) for 21 days. The tissues and plasma samples
were collected 20, 40, 80 and 160 minutes after the single dose administrations and 4 h after the last dose administration in
repeated experiments. In addition, the rats treated with the dose of 1.25 mg kg-1 were maintained until 2 and 8 weeks and the
tissues were taken at these times. The 5-HT levels in the tissue and plasma were measured by using high performance liquid
chromatography (HPLC).
The levels of brain 5-HT were decreased at the single FEN doses when compared with the control group. At the repeated
experiments, although no effect was observed at the dose of 1.25 mg kg-1; decreases were determined in brain 5-HT levels at the
high doses. The levels of 5-HT in the stomach were found to increase in both single and repeated administrations. Decreases in levels
of plasma 5-HT were determined in all experimental groups. In conclusion, while fenfluramine was determined to decrease brain
and plasma 5-HT levels generally, it increased the levels of stomach 5-HT.
Key Words: Fenfluramine, rat, brain, stomach, plasma, serotonin.

Ratlarda Fenfluraminin Kan ve Doku Serotonin (5-Hidroksitriptamin)
Düzeyleri Üzerine Etkileri
Özet: Bu çal›flman›n amac›, ratlarda tek ve tekrarlanan dozlarda uygulanan fenfluramin (FEN)’in beyin, mide ve plazma serotonin (5Hidroksitriptamin, 5-HT) düzeyleri üzerine olan etkilerinin belirlenmesidir. FEN hayvanlara periton içi yolla tek doz (1, 3, 10
µmol/kg) ve a¤›zdan 21 gün süreyle tekrarlanan dozlar (1,25, 5 ve 10 mg/kg) fleklinde uyguland›. Tek doz uygulamalar›n› takiben
20, 40, 80 ve 160. dakikalarda; uzun süreli uygulamalarda ise 21 günlük uygulaman›n bitmesinden 4 saat sonra dokular al›nd›.
Ayr›ca, 1,25 mg/kg dozunda uygulama yap›lan gruptaki hayvanlar ilaç uygulamas› tamamland›ktan sonraki 2 ve 8.haftalara kadar
muhafaza edildi ve dokular› al›nd›. Doku ve plazma 5-HT düzeyleri yüksek bas›nçl› s›v› kromatografi (HPLC) cihaz›nda belirlendi.
Tek doz fenfluramin uygulamas› yap›lan gruplarda beyin 5-HT düzeylerinin kontrol grubuna göre azald›¤›, tekrarlanan uygulamalarda
ise FEN’in 1,25 mg/kg dozunda beyin 5-HT düzeyleri üzerine pek etkili olmad›¤›, buna karfl›l›k yüksek dozlarda azaltt›¤› görüldü.
Mide 5-HT düzeylerinin hem tek hem de tekrarlanan uygulamalarda artt›¤› tespit edildi. FEN’in plazma 5-HT düzeylerinde ise belirgin
bir flekilde azalmalara neden oldu¤u görüldü. Sonuç olarak FEN’in beyin ve plazma 5-HT düzeylerinde azalmaya; mide de ise art›fllara
neden oldu¤u belirlendi.
Anahtar Sözcükler: Fenfluramin, rat, beyin, mide, plazma, serotonin.

Introduction
5-HT is an indolic compound that is synthesized from
the essential amino acid tryptophan. 5-HT synthesis rate
is dependent on the levels of tryptophan in the diet.

Important depots of 5-HT in mammals are
enterochromaffin cells in the gastrointestinal mucosa,
serotonergic neurons of the brain, pineal gland and
platelets. 5-HT can be released from enterochromaffin

* This study was supported by the F›rat University Investigation Foundation (FÜNAF 349).
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cells by acetyl-choline and noradrenergic nerve
stimulation, increased intraluminal pressure and a decline
of intestinal pH (1-6). 5-HT is involved in a variety of
physiological processes, including smooth muscle
contraction, blood pressure regulation and both
peripheral and central nervous system neurotransmission.
In the central nervous system, it acts as a
neurotransmitter-neuromodulator that is implicated in
sleep pattern regulation, appetite control, sexual activity
and aggression. In the periphery, 5-HT acts as a
vasoconstrictor and proaggregator when released from
aggregating platelets. It also acts as a neurotransmitter in
the enteric plexus of the gut and as an autocrine hormone
when released from enterochromaffin cells from the gut,
pancreas and elsewhere (7-10).
Fenfluramine
(FEN),
[N-ethyl-α-methyl-m(trifluoromethyl)phenethylamine] is an appetite
suppressant with proven efficacy. Two forms of the drug
that exhibit similar pharmacology have been prescribed:
the d, l-racemic mixture (FEN) and the more potent disomer (d-FEN). Despite structural similarities to
amphetamine, FEN is not a locomotor stimulant and is
seldom abused. FEN stimulates 5-HT release and inhibits
5-HT reuptake in brain tissue (11-15). In vivo
microdialysis studies in rat brain demonstrate that
systemic or local administration of FEN elevates
extracellular levels of 5-HT. This effect of FEN is blocked
by 5-HT reuptake inhibitors like fluoxetine. Although FEN
influences both 5-HT release and reuptake, the 5 HT
releasing capability of the drug seems to predominate in
vivo (16).
The clinical use of FEN relates to its potential adverse
effects on 5-HT neurons. It is shown that administration
of FEN at sufficient doses can cause long-lasting depletion
of 5-HT and degeneration of 5-HT nerve terminals
throughout the forebrain in laboratory animals.
Depletions of 5-HT are associated with a loss of 5-HT
immunoreactive nerve fibers and a reduction in 5-HT
reuptake sites. 5-HT transporter proteins play an
important role in the release of 5-HT. Like other
amphetamines, FEN release endogenous 5-HT by a
carrier-mediated mechanism involving 5-HT transporter
proteins in cell membranes (7,11,12,17-21).
The aim of this study was to evaluate the short- and
long-term effects of FEN at single and repeated doses on
brain, stomach and plasma 5-HT levels in rats.
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Materials and Methods
Animals and Drug Administrations:
Wistar rats weighing 180-230 g were adapted to
laboratory conditions before use and were maintained in
a room with controlled temperature (20 ± 2 °C), relative
humidity (60%) and 12 h light:12 h dark cycle. Rats
were housed in plastic cages with free access to drinking
water and basal diet. The rats were divided into two main
groups as single and repeated FEN hydrochloride (Sigma
F-8507) administered groups.

Single dose FEN administrations:
Group 1 (Control): (n = 12): Rats received
intraperitoneal (ip) injection of 0.5 ml of distilled water.
Group 2 (n = 24): This group was injected with FEN
1 µmol kg-1 ip in 0.5 ml of distilled water.
Group 3 (n = 24): This group was injected with FEN
3 µmol kg-1 ip in 0.5 ml of distilled water.
Group 4 (n = 24): This group was injected with FEN
10 µmol kg-1 ip in 0.5 ml of distilled water.

Repeated FEN administrations:
Group 5 (Control) (n = 12): Rats received oral
administration of isotonic saline for 21 days.
Group 6 (n = 18): This group was administered FEN
1.25 mg kg-1 orally for 21 days.
Group 7 (n = 18): This group was administered FEN
5 mg kg-1 orally for 21 days.
Group 8 (n = 18): This group was administered FEN
10 mg kg-1 orally for 21 days.
Sample Collection
The animals in groups of the single dose FEN
administrations (Groups 1-4) were decapitated 20, 40,
80 and 160 minutes after the applications. On the other
hand, the animals in the repeated experiments (Group 58) were decapitated 4 h after the last applications. In
addition, the rats treated with the dose of 1.25 mg kg-1,
(Group 6) were maintained until 2 and 8 weeks by only
placebo and the rats were decapitated at these times. The
effects of FEN on body weight in Groups 5, 6, 7 and 8
were assessed by a laboratory balance before and after
the experiments. The tissues and plasma samples were
collected in all groups after the decapitations. Whole brain
and stomach tissues were removed immediately and
stored at -30 °C until the assay. Blood samples were
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collected into tubes (5-7 ml) containing 2% sodium
oxalate and the samples were centrifuged at 3000 rpm to
separate their plasma and stored at -30 °C until the
assay.
Determination of 5-HT Levels
5-HT creatinin sulfate (H-7752) and other chemicals
and reagents were purchased from Sigma (St. Louis, MO,
USA). The homogenization of tissues and plasma was
carried out in a Teflon-glass homogenizer with a buffer
containing 0.02% ascorbic acid in 0.1 M perchloric acid
and centrifuged at 15,000 rpm for 15 min. The
supernatants were pooled. The concentrations of 5-HT
were quantified in the supernatant using HPLC (TSP,
P4000 Quat gradient pomp, FL 3000 detector, AS 3000
autosampler) according to the published methods (22).
After filtration through a 0.45 µ filter, 20 µl aliquots of
clear supernatants were injected into the HPLC with a C
8 reversed phase column (Waters Assoc., stainless steel,
25 cm, 3.9 x 150 mm ID, consisting of 5 µ particle size
octadecylsilica). Mobile phase consisting of 0.01 M
acetate buffer (pH 4.3) in 30% methanol was circulated
at a flow rate of 0.5 ml/min, column temperature 24 ±
1.0 °C. Excitation and emission wavelengths were set at
280 and 350 nm, respectively. The levels of 5-HT in the
tissues were calculated using a computer program (OS/2
Systems) on HPLC.

Statistical Analysis
All results were expressed as mean ± SEM.
Comparisons of groups were evaluated by one-way
ANOVA followed by Duncan’s test in SPSS for Windows.
The results were considered statistically significant when
P < 0.05.

Results
Tissue and plasma 5-HT levels in animals treated with
single and repeated doses of FEN are shown in Tables 16. Treatment with a single dose of FEN caused significant
decreases in brain 5-HT levels at 20 min when compared
with the control group and these levels were observed to
be at the minimal level at 160 min (Table 1). After the
repeated administrations of FEN at 4 hours, no change
was detected in brain 5-HT levels in Group 6 when
compared with the control group, but slight decreases
were observed in Groups 7 and 8. On the other hand,
brain 5-HT levels at 2 and 8 weeks were decreased by
FEN in Group 6 (Table 2).
When compared with the control group
administration of single doses of FEN to rats caused
decreases in stomach 5-HT levels in Group 2, but
increases were observed in Groups 3 and 4 at 20 min.
However, increases in stomach 5-HT levels were

Table 1. Brain 5-HT levels (ppb) in rats treated with single doses of FEN.

20th min
th

40 min
th

80 min
th

160 min
a, b, c

Group1
(Control)

Group 2
(1µmol kg-1)

Group 3
(3 µmol kg-1)

Group 4
(10 µmol kg-1)

54.9 ± 3.2a

38.2 ± 2.2b

34.2 ± 3.0c

30.4 ± 3.4c

2.9a

4.2a

2.4b

35.7 ± 2.5b

54.9 ±

47.8 ±

28.5 ±

53.3 ± 1.8a

41.3 ± 2.8b

27.9 ± 3.3c

26.1 ± 1.7c

2.5a

2.6b

3.6b

25.2 ± 3.4b

54.0 ±

29.3 ±

23.3 ±

: The differences between values marked with different letters on the same line are significant. P < 0.05 (Compared to control group).

Table 2. Brain 5-HT levels (ppb) in rats treated with repeated doses of FEN.

4th hour
nd

2 week
th

8 week
a, b, c

Group 5
(Control)

Group 6
(1.25 mg kg-1)

Group 7
(5.0 mg kg-1)

Group 8
(10 mg kg-1)

54.9 ± 3.5a

54.6 ± 3.4a

45.9 ± 5.1b

44.8 ± 2.4b

53.2 ±

1.4a

34.1 ±

3.9b

-

-

55.9 ±

4.2a

29.8 ±

1.9b

-

-

: The differences between values marked with different letters on the same line are significant. P < 0.05 (Compared to control group).
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observed at 40, 80 and 160 min when compared with
the control group in Groups 3 and 4 (Table 3). Repeated
administrations of FEN caused increases in stomach 5-HT
levels at 4 h. in all groups according to the control group.
Similarly, significant increases were also detected in
stomach 5-HT levels at 2 and 8 weeks in Group 6 (Table
4).

in the control group (Group 5) while significant decreases
(21.7%, 9.3% and 29.9%) were noted in Groups 6, 7
and 8, respectively.

Discussion
The amphetamine derivatives d, l-FEN and d-FEN had
been widely used as appetite suppressants until their
removal from the market due to serious side-effects.
High doses of FEN cause long term degeneration of 5-HT
nerve terminals throughout the forebrain. These
degenerations include depletion of tissue 5-HT, decreased
5-HT biosynthesis, and loss of 5-HT transporters (SERT)
(12,13). Recently, it has been shown that FEN causes the

Significant decreases in plasma 5-HT levels were
observed in both single and repeated administrations of
FEN to rats in all times when compared with the control
groups (Tables 5 and 6).
The changes in body weights of animals treated with
the repeated doses of FEN are shown in Table 7. A
significant increase in body weight (17.1%) was observed

Table 3. Stomach 5-HT levels (ppb) in rats treated with single dose of FEN.
Group 1
(Control)

Group 2
(1µmol kg-1)

Group 3
(3 µmol kg-1)

Group 4
(10 µmol kg-1)

20th min

489 ± 34a

446 ± 33a

533 ± 16b

656 ± 36c

40th min

467 ± 41a

651 ± 35b

749 ± 54c

444 ± 39a

22a

32ab

45c

617 ± 43b

754 ± 22c

689 ± 19ab

th

80 min

480 ±

160th min

472 ± 44a

a, b, c

687 ±

651 ± 27b

770 ±

: The differences between values marked with different letters on the same line are significant. P < 0.05 (Compared to control group).

Table 4. Stomach 5-HT levels (ppb) in rats treated with repeated doses of FEN.
Group 5
(Control)

Group 6
(1.25 mg kg-1)

Group 7
(5.0 mg kg-1)

Group 8
(10 mg kg-1)

4th hour

477 ± 54a

774 ± 28b

895 ± 34c

953 ± 63c

2nd week

526 ± 40a

696 ± 39b

-

-

38a

51b

-

-

th

8 week
a, b, c

467 ±

726 ±

: The differences between values marked with different letters on the same line are significant. P < 0.05 (Compared to control group).

Table 5. Plasma 5-HT levels (ppb) in rats treated with single dose of FEN.

20th min
th

Group 1
(Control)

Group 2
(1µmol kg-1)

Group 3
(3 µmol kg-1)

Group 4
(10 µmol kg-1)

546 ± 40a

235 ± 37b

260 ± 13b

311 ± 22c

22a

31b

26c

354 ± 32b

40 min

502 ±

80th min

523 ± 16a

280 ± 29b

434 ± 34c

463 ± 34c

25a

30b

17b

203 ± 18b

th

160 min
a, b, c

860

549 ±

294 ±

281 ±

463 ±

251 ±

: The differences between values marked with different letters on the same line are significant. P < 0.05 (Compared to control group).
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Table 6. Plasma 5-HT levels (ppb) in rats treated with repeated doses of FEN.
Group 5
(Control)

Group 6
(1.25 mg kg-1)

Group 7
(5.0 mg kg-1)

Group 8
(10 mg kg-1)

4th hour

676 ± 34a

484 ± 14b

341 ± 41c

241 ± 29c

2nd week

567 ± 44a

542 ± 21a

-

-

37a

332 ± 33b

-

-

th

8 week
a, b, c

641 ±

: The differences between values marked with different letters on the same line are significant. P < 0.05 (Compared to control group).

Table 7. Changes of body weight (%) in rats treated with repeated doses of FEN.

Group 5 (Control)

Body Weight at the
Beginning of Experiments
(g)

Body Weight at the
End of Experiments
(g)

Changes in
Body Weight
(%)

156.6 ± 17a

183.3 ± 14b

+ 17.1

22a

26b

- 21.7

Group 6

190.0 ±

Group 7

230.0 ± 31a

213.3 ± 19a

- 09.3

Group 8

12a

13b

- 29.9

a, b

223.1 ±

148.8 ±

156.6 ±

: The differences between values marked with different letters on the same line are significant. P < 0.05 (Compared to control group).

release of 5-HT from nerve terminals and inhibits 5-HT
reuptake in in vitro investigations (14,17). However, in
vivo microdialysis studies demonstrated that
administration of FEN elevates extracellular levels of 5HT in intact brain. Like other amphetamines, FEN
releases endogenous 5-HT by a carrier-mediated
mechanism involving SERT proteins in cell membranes
(16,23-25). In our study, the levels of 5-HT in the brain
have been shown to decrease when compared with the
control group, especially at the single high doses (3 and
10 µmol kg-1) of FEN in rats. These observations
indicated that FEN may decrease 5-HT levels in the rat
brain due to the inhibition of 5-HT reuptake and to the
stimulation of 5-HT release from nerve cells.
Caccia et al. (19) reported that brain 5-HT levels
decreased after 4 h in 3-week administration of FEN the
same as acute applications dependent on doses. In
addition, two weeks after 1.25 mg kg-1 of FEN was
decreased to minimal levels but increases in brain 5-HT
levels showed at 8 weeks. In this study, although no
important changes were observed in brain 5-HT levels at
repeated administration of 1.25 mg kg-1 FEN, significant
decreases were determined at the doses of 5 and 10 mg
kg-1 when compared with the control group. However,

decreases in 2 and 8 weeks after 1.25 mg kg-1 in brain
5-HT levels were noted. The observations of the present
study are in accordance with the findings of Caccia et al.
(19) and indicated that repeated administration of FEN
causes prolonged depletion of brain 5-HT.
The majority of 5-HT is found in enterochromaffin
cells of the gastrointestinal tract in animals. In these
structures, it accounts for approximately 80% of total
body 5-HT content. Released 5-HT from these cells by
stimulations can be detected in intestinal lumen and
systemic circulation (1,15). Costa et al. (15) showed that
5-HT levels in the stomach increased slightly at high doses
of FEN in rats. Our results also show that single doses of
FEN increased stomach 5-HT levels irregularly, but
repeated administrations of FEN elevated these levels
dependent on doses. These results for the effects on
stomach 5-HT levels of FEN are in accordance with the
findings of the above researchers.
The majority of platelet 5-HT originates from
enterochromaffin cells. Circulation plasma 5-HT is taken
up by platelets mainly by an active transport mechanism.
In the circulation, it is almost entirely confined to platelets
and thereby rendered functionally inactive. Some
investigators (2,26-28) showed that carcinoid tumors,
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during long-term 5-HT rich-foods ingestion and longterm FEN administrations, caused an increase in
circulating plasma. However, 5-HT is stored in platelets
and circulating 5-HT levels are therefore decreased.
Finally, a decrease in circulating 5-HT levels was
determined. Our results for the circulating 5-HT levels
showed that FEN may decrease circulating 5-HT levels in
rats due to storage in platelets. The observation of the
above researchers is in agreement with the results of the
present study.
In rats, FEN is quite effective in reducing food
consumption, possibly because of its ability to enhance
serotoninergic transmission by potentiating the release of

5-HT and inhibiting its inactivation by reuptake.
Investigators showed that long-term FEN administrations
caused a dramatic reduction of body weight gain
(10,12,17,20). The decreases in body weight observed in
this study are in accordance with the reports of the above
researchers and can be explained by the effects of FEN on
brain 5-HT levels.
In conclusion, we showed that single and long-term
administrations of FEN induced decreases in brain and
plasma 5-HT levels but increased stomach levels.
Therefore, significant decreases were observed in body
weight in long-term administrations of FEN, especially at
high doses.
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